It was previously shown that the fusion of IFNα mutein IFNα R149A, with a 200-fold reduced affinity for the IFNAR2, to a cancer-directed antibody is less likely to bind to IFNAR expressed on normal cells, thus potentially reducing deleterious off-cancer side effects while ‘en route’ to cancer cells [11,12]. The gene discussed is IFNA2; the disease is cancer.